Document is current
Any future updates will be listed below
-
Authors
Balinda, Henriette U.
Kelly, William J. https://orcid.org/0000-0003-4491-3541
Kaklamani, Virginia G.
Lathrop, Kate I.
Canola, Marcela Mazo
Ghamasaee, Pegah
Sareddy, Gangadhara R. https://orcid.org/0000-0001-9977-3932
Michalek, Joel
Gilbert, Andrea R.
Surapaneni, Prathibha
Tiziani, Stefano https://orcid.org/0000-0002-7230-0307
Pandey, Renu
Chiou, Jennifer
Lodi, Alessia
Floyd, John R. II
Brenner, Andrew J.
-
Funding
Funding for this research was provided by:
METAvivor
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016672)
Cancer Prevention and Research Institute of Texas (RP210164)
- License Information
-
More Information
Article History
Received: 13 March 2024
Accepted: 15 July 2024
First Online: 7 August 2024
Competing interests
: HB, WK, KL, PG, GS, JM, AG, PS, ST, RP, JC, AL, JF and AB have no personal, professional or financial relationships that would constitute a conflict of interest. VK and MC are on the speaker’s bureau and VK is a consultant for Gilead. Portions of this work have previously been presented in abstract form at the 2023 Society for NeuroOncology Annual Meeting, San Antonio Breast Cancer Symposium 2022 and 2024, and the European Society for Medical Oncology Virtual Congress 2020. WK and AB have received contracted funding from Gilead for a similar study.
: This research has included local researchers throughout the research process and is locally relevant with 40% of the patients identifying as Hispanic or Latino.
